Three MD Anderson researchers elected AAAS Fellows
Three researchers at The University of Texas MD Anderson Cancer Center have been named fellows of the American Association for the Advancement of Science (AAAS) for their notable contributions to the field of cancer research. This distinction is one of the highest honors in the scientific research community.
Stephen Lai, M.D., Ph.D., Cullen Taniguchi, M.D, Ph.D., and Apostolia Tsimberidou, M.D., Ph.D., now join this distinguished...
Targeted therapy momelotinib provides significant symptom and anemia improvements in patients with myelofibrosis
Patients with myelofibrosis had clinically significant improvement in disease-related symptoms, including anemia and spleen enlargement, when...
MD Anderson EGFR Classification licensed by BostonGene and Tempus to provide new insight on atypical mutations in lung cancer
The University of Texas MD Anderson Cancer Center today announced licensing agreements with BostonGene Corporation and Tempus for the MD Anderson...
MD Anderson’s Jennifer Wargo receives TAMEST O’Donnell Award for pioneering microbiome research
Jennifer Wargo, M.D., professor of Surgical Oncology and Genomic Medicine at The University of Texas MD Anderson Cancer Center, has received a 2023 Edith and Peter O’Donnell Award in Medicine from the Texas Academy of Medicine, Engineering, Science and Technology (TAMEST) for her contributions to the understanding of how the gut microbiome influences responses to immunotherapy and other cancer treatments.
The O’Donnell Awards are...
Scientists develop novel mRNA delivery method using extracellular vesicles
A team of researchers led by The University of Texas MD Anderson Cancer Center has developed a novel delivery system for messenger RNA (mRNA...
MD Anderson Research Highlights for January 11, 2023
The University of Texas MD Anderson Cancer Center’s Research Highlights provides a glimpse into recent basic, translational and clinical cancer...
Novel T cell receptor therapy shows early anti-tumor activity
Afamitresgene autoleucel (afami-cel; formerly ADP-A2M4), an adoptive T cell receptor (TCR) therapy targeting the MAGE-A4 cancer antigen, achieved...